Chemopreventive and therapeutic potential of "Naringenin," a flavanone present in citrus fruits

Nutrition and Cancer

Volumn 67, Issue 1, 2015, Pages 27-42

  Mir, Irfan Ahmad ^a   Tiku, Ashu Bhan ^b  

^a UNIVERSITY OF KASHMIR   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; NARINGENIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ANTINEOPLASTIC AGENT; ANTIOXIDANT; FLAVANONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON CANCER; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; FOOD COMPOSITION; GLIOMA; HUMAN; HYPERSENSITIVITY; INFLAMMATORY BOWEL DISEASE; LIVER CANCER; LUNG CANCER; LUNG FIBROSIS; NERVE DEGENERATION; NONHUMAN; PANCREAS CANCER; RADIATION PROTECTION; SKIN CANCER; ANALYSIS; ANIMAL; CHEMISTRY; CITRUS; DIET SUPPLEMENTATION; DIET THERAPY; FRUIT; FUNCTIONAL FOOD; METABOLISM; NEOPLASMS; TOMATO;

CITRUS; LYCOPERSICON ESCULENTUM;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; CITRUS; DIETARY SUPPLEMENTS; FLAVANONES; FRUIT; FUNCTIONAL FOOD; HUMANS; LYCOPERSICON ESCULENTUM; NEOPLASMS;

EID: 84920506588     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.976320     Document Type: Article

References (148)

1. Miller PE and Snyder DC: Phytochemicals and cancer risk: a review of the epidemiological evidence. Nutrition and Clinical Practice 27, 599-561, 2012.
2. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Helifvaara M, et al.: Flavonoid intake and risk of chronic diseases. American Journal of Clinical Nutrition 76, 560-568, 2002.
3. Patil BS, Jayaprakasha GK, Chidambara Murthy KN, and Vikarm A: Bioactive compounds: historical perspectives, opportunities, and challenges. Journal Agriculture and Food Chemistry 57, 8142-8160, 2009.
4. Crozier A, Del Rio D, and Clifford MN: Bioavailability of dietary flavonoids and phenolic compounds. Molecular Aspects of Medicine 31, 446-467, 2010.
5. Salminen A, Kauppinen A, and Kaarniranta K: Phytochemicals suppress nuclear factor-kB signaling: impact on health span and the aging process. Current Opinion in Clinical Nutrition and Metabolic Care 15, 23-28, 2012.
6. Frei B, Stocker R, England L, and Ames BN: Ascorbate: The most effective antioxidant in human blood plasma. Advance in Experimental Medicine and Biology 264, 155-163, 1990.
7. Ajay M and Mustafa MR: Effects of ascorbic acid on impaired vascular reactivity in aortas isolated from age-matched hypertensive and diabetic rats. Vascular Pharmacology 45, 127-133, 2006.
8. Aoi W, Naito Y, Takanami Y, Ishii T, Kawai Y, et al.: Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification. Biochemical and Biophysical Research Communications 366, 892-897, 2008.
9. Stahl W and Sies H: Bioactivity and protective effects of natural carotenoids. Biochimica et Biophysica Acta 1740(2), 101-10, 2005.
10. Kumar R, Saha A, and Saha D: A new antifungal coumarin from Clausena excavate. Fitoterapia 83(1), 230-233, 2012.
11. Bhattacharyya SS, Paul S, De A, Das D, Samadder A, et al.: Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: Cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicology and Applied Pharmacology 253, 270-281, 2011.
12. Reddy AC and Lokesh BR: Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and oxidation ferrous iron. Molecular Cell Biochemistry 137, 1-8, 1994.
13. Aggarwal BB and Harikumar KB: Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The International Journal of Biochemistry & Cell Biology 41, 40-59, 2009.
14. Min SW, Ryu SN, and Kim DH: Anti-inflammatory effects of black rice, cyanidin-3-O-b-D-glycoside, and its metabolites, cyanidin and protocatechuic acid. International Immunopharmacology 10, 959-966, 2010.
15. Cho KW, Lee OH, Banz WJ, Moustaid-Moussa N, Shay NF, et al.: Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARg transcriptional activity. Journal of Nutritional Biochemistry 21, 841-847, 2010.
16. Choi EJ and Kim GH: Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine 15, 683-690, 2008.
17. Kar Mahapatra S, Chakraborty SP, Majumdar S, Bag BG, and Roy S: Eugenol protects nicotine-induced superoxide mediated oxidative damage in murine peritoneal macrophages in vitro. European Journal of Pharmacology 623, 132-140, 2009.
18. Khan AQ, Khan R, Qamar W, Lateef A, Rehman MU, et al.: Geraniol attenuates 12-O-Tetradecanoylphorbol-13-Acetate (TPA)-induced oxidative stress and inflammation in mouse skin: Possible role of p38 MAP Kinase and NF-kB. Experimental and Molecular Pathology 94, 419-429, 2013.
19. Nazari M, Ghorbani A, Hekmat-Doost A, Jeddi-Tehrani M, and Zand H: Inactivation of Nuclear Factor-kB by citrus flavanone hesperidin contributes to apoptosis and chemo-sensitizing effect in Ramos cells. European Journal of Pharmacology 650, 526-533, 2011.
20. Kalpana KB, Devipriya N, Srinivasan M, Vishwanathan P, Thayalan K, et al.: Evaluating the radioprotective effect of hesperidin in the liver of Swiss albino mice. European Journal of Pharmacology 658, 206-212, 2011.
21. Zhang X, Cao J, Jiang L, Geng C, and Zhong L: Protective effect of hydroxytyrosol against acrylamide-induced cytotoxicity and DNA damage in HepG2 cells. Mutation Research 664(1-2), 64-68, 2009.
22. Deiana M, Incani A, Rosa A, Atzeri A, Loru D, et al.: Hydroxytyrosol glucuronides protect renal tubular epithelial cells against H2O2 induced oxidative damage. Chemico-Biological Interactions 193, 232-239, 2011.
23. Xiao HB, Jun-Fang, Lu XY, Chen XJ, Chao-Tan, et al.: Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level. European Journal of Pharmacology 616(1-3), 213-222, 2009.
24. Kang GY, Lee ER, Kim JH, Jung JW, Lim J, et al.: Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells. European Journal of Pharmacology 611(1-3), 17-21, 2009.
25. Orhan N, Aslan M, Demirci B, and Ergun F: A bioactivity guided study on the antidiabetic activity of Juniperus oxycedrus subsp. Oxycedrus L. leaves. Journal of Ethnopharmacology 140, 409-415, 2012.
26. Turek JJ, Li Y, Schoenlein IA, Allen KGD, and Watkins BA: Modulation of macrophage cytokine production by conjugated linoleic acids is influenced by the dietary n-6:n-3 fatty acid ratio. Nutritional Biochemistry 9, 258-266, 1998.
27. Burton GW, Joyce A, and Ingold KU: First proof that vitamin E is major lipid-soluble, chain-breaking antioxidant in human blood plasma. The Lancet 2, 327, 1982.
28. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, et al.: Vitamin E consumption and the risk of coronary disease in women. New England Journal of Medicine 328, 1444-1449, 1993.
29. Stone WL and Papas AM: Tocopherols and the etiology of colon cancer. Journal of National Cancer Institute 89, 1006-1014, 1997.
30. Duthie GG, Gardner PT, and Kyle JA: Plant polyphenols: are they the new magic bullet?. Proceeding of the Nutrition Society 62, 599-603, 2003.
31. Fraga CG, Galleano M, Verstraeten SV, and Oteiza PI: Basic biochemical mechanisms behind the health benefits of polyphenols. Molecular Aspects of Medicine 31, 435-445, 2010.
32. Romagnolo DF and Selmin OI: Flavonoids and cancer prevention: a review of the evidence. Journal of Nutrition in Gerontology and Geriatrics 31, 206-238, 2012.
33. Scalbert A and Williamson G: Dietary intake and bioavailability of polyphenols. Journal of Nutrition 130(8S Suppl), 2073S-2085S, 2000.
34. Kyselova Z: Toxicological aspects of the use of phenolic compounds in disease prevention. Interdisciplinary Toxicology 4, 173-183, 2011.
35. Felgines C, Texier O, Morand C, Manach C, Scalbert A, et al.: Bioavailability of the flavanone Naringenin and its glycosides in rats. American Journal of Gastrointestinal and Liver Physiology 279, G1148-G1154, 2000.
36. Krishnakumar N, Nechikkad S, Nagarajan RP, and Subburayan K: Enhanced anticancer activity of NGN-loaded nanoparticles in human cervical (HeLa) cancer cells. Biomedicine & Preventive Nutrition 1, 223-231, 2011.
37. Erlund I: Review of the flavonoids quercetin, hesperetin, and Naringenin. Dietary sources, bioactivitiess, bioavaliability, and epidemiology. Nutrition Research 24, 851-874, 2004.
38. Slimestad R and Verheul M: Properties of chalconargenin and rutin isolated from cherry tomatoes. Journal of Agriculture Food Chemistry 59, 3180-3185, 2011.
39. Yagura T, Motomiya T, Ito M, Honda G, Lida A, et al.: Anticarcinogenic compounds in the Uzbek medicinal plant, Helichrysum Maracandicum. J Nature Medicine 62, 174-178, 2008.
40. Iwamura C, Shinoda K, Yoshimura M, Watanabe Y, Obata A, et al.: Naringenin chalcone suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells. Allergology International 59, 67-73, 2010.
41. Funaguchi N, Ohno Y, La BL, Asai T, Yuhgetsu H, et al.: Narirutin inhibits airway inflammation in an allergic mouse model. Clinical and Experimental Pharmacology and Physiology 34, 766-770, 2007.
42. Bae JT, Ko HJ, Kim GB, Pyo HB, and Lee GS: Protective effects of fermented citrus unshiu peel extract against ultraviolet-A-induced photoageing in human dermal fibroblasts. Phytotherapy Research 26, 1851-1856, 2012.
43. Ha SK, Park HY, Eom H, Kim Y, and Choi I: Narirutin Fraction from citrus peels attenuates LPS-stimulated inflammatory response through inhibition of NF-kB and MAPKs activation. Journal of Food and Chemical Toxicology 50, 3498-3504, 2012.
44. Yang CP, Liu MH, Zou W, Guan XL, Lia L, et al.: Toxicokenitics of Naringin and its metabolite Naringenin after 180-day repeated oral administration in beagle dogs assayed by a rapid resolution liquid chromatography/ tandem mass spectrometric method. Journal of Asian Natural Products Research 14, 68-75, 2012.
45. Kuo YJ, yang YC, Zhan LJ, Wu MD, Kuo LM, et al.: Flavanone and diphenylpropane Glycosides and glycosidic acyl esters from viscum articulatum. Journal of Natural Products 73, 109-114, 2010.
46. Han X, Ren D, Fan P, Shen T, and Lou H: Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. European Journal of Pharmacology 581(1-2), 47-53, 2008.
47. Delmulle L, Vanden Berghe T, Keukeleire DD, and Vandenabeele P: Treatment of PC-3 and DU145 prostate cancer cells by prenylflavonoids from hop (Humulus lupulus L.) induce a caspase-independent form of cell death. Phytotherapy Research 22, 197-203, 2008.
48. Shirataki Y, Motohashi N, Tani S, Sakagami H, Satoh K, et al.: In vitro biological activity of prenylflavanones. Anticancer Research 21(1A), 275-280, 2001.
49. Nkengfac AC, Sanson, Tempesta, and Forum ZT: Two new flavonoids from Erythrina eriotriocha. Journal of Natural Products 52, 320-324, 1989.
50. Cui L, Ndinteh DT, Na M, Thuong PT, Silike-Muruumu J, et al.: Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. Journal Natural Products 70, 1039-1042, 2007.
51. Fukui H, Goto K, and Tabata M: Two antimicrobial Flavonones from the leaves of Glycyrrhiza glabra. Journal of Chemical and Pharmaceutical Bulletin (Tokyo) 36, 4174-4176, 1988.
52. Rezk BM, Haenen GR, Van der vijgh WJ, and Bast A: The antioxidant activity of Phloretin: The disclosure of a new antioxidant phramacophore in flavonoids. Biochemical and Biophysical Research Communication 295, 9-13, 2002.
53. Lee JH, Regmi SC, Kim JA, Cho MH, Yun H, et al.: Apple flavonoid Phloretin inhibits Escherichia coli 0157: H7 bioflim formation and ameliorates colon inflammation in rats. Infection and Immunity 79, 4819-4827, 2011.
54. Lu XY, Zeng YY, Ye YX, Zhou YY, Mu JJ, et al.: Anti inflammatory and immunosuppressant effects of phloretin. Yao Xue Xue Bao (Acta pharmaceutica sinica) 44, 480-485, 2009.
55. Vasantha RHP and Yasmin A: Inhibition of oxidation of aqueous emulsion of Omega-3 fatty acids and fish oil by Phloretin and phloridzin. Molecules 15, 251-257, 2010.
56. Gao SS, Chen XY, Zhu RZ, Choi BM, Kim SJ, et al.: Dual effects of Phloretin on aflatoxin B1 metabolism: activation and detoxification of aflatoxin B1. Biofactors 38, 34-43, 2012.
57. Janicke B, Hegardt C, Krogh M, Onning G, Akesson B, et al.: The antiproliferative effects of dietary fiber phenolic compounds Ferulic acid and p-Coumaric acid on the cell cycle of CaCo-2 cells. Nutrition and Cancer 63, 611-622, 2011.
58. Roelens F, Heldring N, Dhooge W, Bengtsson M, Comhaire F, et al.: Subtle side-chain modification of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptor alpha and beta. Journal of Medicinal Chemistry 49, 7357-7365, 2006.
59. Bugianesi R, Catasta G, Spigno P, D'Uva A, and Maiani G: Naringenin from cooked tomato paste is bioavailable in men. Journal of Nutrition 132, 3349-3352, 2002.
60. Ross JA and Kasum CM: Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annual Review of Nutrition 22, 19-34, 2002.
61. Manach C, Scalbert A, Morand C, Remesy C, and Jimenez L: Polyphenols: Food sources and bioavailability. American Journal of Clinical Nutrition 79, 727-747, 2004.
62. Jovanovich SV, Steenken S, Simic MG, and Hara Y: Antioxidant properties of flavonoids: Reduction potentials and electron transfer reactions of Flavonoids radicals. In: Flavonoids in Health and Disease, Rice-Evans CA and Packer L (eds.). New York: Marcel Dekker, 1998, pp. 137-161.
63. Spencer JP, Chowrimootoo G, Choudhury R, Debnam, ES, Srai SK, et al.: The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Letters 458, 224-230, 1999.
64. Bolli A, Marino M, Rimbach G, Fanali G, Fasano M, et al.: Flavonoid binding to human serum albumin. Biochemical and Biophysical Research Communications 398, 444-449, 2010.
65. Maiti K, Mukherjee K, Gantait A, Saha BP, and Mukherjee PK: Enhanced therapeutic potential of Naringenin-phospholipid complex in rats. Journal of Pharmacy and Pharmacology 58, 1227-1233, 2006.
66. Wen J, Liu B, Yuan E, Ma Y, Zhu Y: Preparation and physicochemical properties of the complex of naringenin with hydroxypropyl-b-cyclodextrin. Molecules 15, 4401-4407, 2010.
67. Shulman M, Cohen M, Soto-Gutierrez A, Yagi H, Wang H, et al.: Enhancement of NGN bioavailability by complexation with hydroxypropyl-b-cyclodextrin. PLoS ONE 6(4), 18033, 2011.
68. Yen FL, Wu TH, Lin LT, Cham TM, and Lin CC: Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effect of naringenin in orally- administrated rats with CCl4-induced acute liver failure. Pharmaceutical Research 26, 893-902, 2009.
69. Krishnakumar N, Sulfikkarali N, Rajendra Prasad N, and Karthikeyan S: Enhanced anticancer activity of naringenin-loaded nanoparticles in human cervical (HeLa) cancer cells. Biomed Prev Nutr 1, 223-231, 2011.
70. Sulfikkarali N, Krishnakumar N, Manoharan S, and Nirmal RM: Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz( a)anthracene induced experimental oral carcinogenesis. Pathology and Oncology Research 19, 287-296, 2013.
71. Formica JV and Regelson W: Review of the biology of quercetin and related bioflavonoids. Food and Chemical Toxicology 33, 1061-1080, 1995.
72. Crespy V, Morand C, Besson C, Manach C, Demigne C, et al.: Quercetin, but not its glycosides, is absorbed from the rat stomach. Journal of Agriculture and Food Chemistry 50, 618-621, 2002.
73. Silberberg M, Gilizquierdo A, Combaret L, Remesy C, Scalbert A, et al.: Flavanone metabolism in healthy and tumor-bearing rats. Biomedicine and Pharmacotherapy 60, 529-535, 2006.
74. Erlund I, Meririnne E, Alfthan G, and Aro A: Plasma kinetics and urinary excretion of the flavanones NGN and hesperetin in humans after ingestion of orange juice and grapefruit juice. Journal of Nutrition 131, 235-241, 2001.
75. Fuhr U, Klittich K, and Staib AH: Inhibitory effect of grapefruit juice and its bitter principal, Naringenin, on CYP1A2 dependent metabolism of caffeine in man. British Journal of Clinical Pharmacology 35, 431-436, 1993.
76. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, and Kolonel LN: Intake of flavonoids and lung cancer. Journal of National Cancer Institute 92, 154-160, 2000.
77. Neuhoser ML: Review-dietary flavonoids and cancer risk: Evidence from population based study. Nutrition and Cancer 50(1), 1-7, 2004.
78. So FV, Guthrie N, Chambers AF, Moussa M, and Carroll KK: Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutrition and Cancer 26, 167-181, 1996.
79. Poon CH, Wong TY, Wang Y, Tsuchiya Y, Nakajima M, et al.: The citrus flavanone Naringenin suppresses CYP1B1 transactivation through antagonizing xenobiotic-responsive element binding. Molecular Nutrition 109, 1598-1605, 2013.
80. Leonardi T, Vanamala J, Taddeo SS, Davidson LA, Murphy ME, et al.: Apigenin and Naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-Treated rats. Experimental Biology and Medicine (Maywood) 235, 710-717, 2010.
81. Ekambaram G, Rajendran P, Magesh V, and Sakthisekaran D: Naringenin reduces tumor size and weight lost in N-methyl-N'-nitro-Nnitrosoguanidine-induced gastric carcinogenesis in rats. Nutrition Research 28, 106-112, 2008.
82. Subramanian P and Arul D: Attenuation of NDEA- induced hepatocarcinogenesis by the Naringenin in rats. Cell Biochemistry and Function 31, 511-517, 2013.
83. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Patnaik S, et al.: Naringenin protects HaCaT human keratinocytes against UVB-induced apoptosis and enhances the removal of cyclobutane pyrimidine dimers from the genome. Photochemistry and Photobiology 84, 307-316, 2008.
84. Saija A, Tomaino A, Trombetta D, Giacchi M, Pasquale AD, et al.: Influence of different penetration enhancers on in vitro skin permeation and in vivo photoprotective effect of flavonoids. International Journal of Pharmaceutics 175, 85-94, 1998.
85. Sabarinathan D and Vanisree AJ: Naringenin, a flavanone alters the tumorigenic features of C6 glioma cells. Biomedicine & Preventive Nutrition 1, 19-24, 2011.
86. Raza SS, Khan MM, Ahmad A, Ashafaq M, Islam F, et al.: Neuroprotective effect of Naringenin is mediated through suppression of NF-kB signaling pathway in experimental stroke. Journal of Neuroscience 230, 157-171, 2013.
87. Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, et al.: Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Molecular Therapy 15, 2194-2202, 2007.
88. Qin L, Jin L, Lu L, Lu X, Zhang C, et al.: Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell 2, 507-516, 2011.
89. Page GG and Ben-Eliyahu S: Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Research and Treatment 45, 159-167, 1997.
90. Faist E, Kupper TS, Baker CC, Chaudry IH, Dwyer J, et al.: Depression of cellular-immunity after major injury-its association with post traumatic complications and its reversal with immunomodulation. Archives of Surgery-Chicago 121, 1000-1005, 1986.
91. Hogan BV, Peter MB, Shenoy HG, Horgan K, and Hughes TA: Surgery induced immunosuppression. Surg-J R Coll Surg E 9, 38-43, 2011.
92. Du G, Jin L, Han X, Song Z, Zhang H, et al.: Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Research 69, 3205-3212, 2009.
93. Frydoonfar HR, McGrath DR, and Spigelman AD: The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid NGN. Colorectal Disease 5, 149-152, 2003.
94. Vanamala J, Leonardi T, Patil BS, Taddeo SS, Murphy ME, et al.: Suppression of colon carcinogenesis by bioactive compounds in grapefruit. Carcinogenesis 27, 1257-1265, 2006.
95. Arul D and Subramanian P: Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathology and Oncology Research 19, 763-770, 2013.
96. Suzuki K and Matsubara H: Recent advances in p53 research and cancer treatment. Journal of Biomedicine and Biotechnology 2011, 978312, 2011. doi:10.1155/2011/978312
97. Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death and Differentiation 18, 1414-1424, 2011.
98. Kalra M, Mayes J, Assefa S, Kaul AK, and Kaul R: Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World Journal of Gastroenterology 14, 5945-5961, 2008.
99. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, et al.: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal regulated kinase 2 activation. Cancer Research 61, 4222-4228, 2001.
100. Yang Y, Xu Y, Xia T, Chen F, Zhang C, et al.: A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-b ligand-receptor binding. Chem Commun (Camb) 47, 5440-5442, 2011.
101. Liu X, Wang W, Hu H, Tang N, Zhang C, et al.: Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharmaceutical Research 23, 82-89, 2006.
102. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al.: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Research 69, 5820-5828, 2009.
103. Lou C, Zhang F, Yang M, Zhao J, Zeng W, et al.: Naringenin decreases invasiveness and metastasis by inhibiting TGF-b-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLOS One 7(12), 50956, 2012.
104. Gao K, Henning SM, Niu Y, Youssefian AA, Seeram NP, et al.: The citrus flavonoid Naringenin stimulates DNA repair in prostate cancer cells. Journal of Nutritional Biochemistry 17, 89-95, 2006.
105. Ratna WN and Simonelli JA: The action of dietary phytochemicals quercetin, catechin, resveratrol and naringenin on estrogen-mediated gene expression. Life Sciences 70,1577-1589, 2002.
106. Lee JH, Park CH, Jung KC, Rhee HS, and Yang CH: Negative regulation of b-catenin/Tcf signaling by Naringenin in AGS gastric cancer cell. Biochemical and Biophysical Research Communications 335, 771-776, 2005.
107. Huang YC, Yang CH, and Chiou YL: Citrus flavanone Naringenin enhances melanogenesis through the activation of Wnt/b-catenin signalling in mouse melanoma cells. Phytomedicine 18, 1244-1249, 2011.
108. Guerreiro S, Monteiro, R, Calhau C, Azevedo I, and Soares R: Naringenin inhibits cell growth and migration in human breast cancer cell lines. The FASEB Journal 21, 848.5, 2007 (Abstract).
109. Bulzomi P, Bolli A, Galluzzo P, Leone S, Acconcia F, et al.: Naringenin and 17b-estradiol coadministration prevents hormone-induced human cancer cell growth. International Union of Biochemistry and Molecular Biology Life 62, 51-60, 2010.
110. Tate P, Acconcia F, Leone S, Cardillo I, and Marino M: Mechanisms of NGN-induced apoptotic cascade in cancer cells: involvement of estrogen receptor a and b signalling. International Union of Biochemistry and Molecular Biology Life 56, 491-499, 2004.
111. Park JH, Jin CY, Lee BK, Kim GY, Choi YH, et al.: Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells. Food and Chemical Toxicology 46, 3684-3690, 2008.
112. Jin CY, Park C, Lee JH, Chung KT, Kwon TK, et al.: NGN-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells. Toxicology in Vitro 23, 259-265, 2009.
113. Kanno S, Tomizawa A, Ohtake T, Koiwai T, Ujibe M, et al.: Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicology Letter 166, 131-139, 2006.
114. Imai Y, Tsukahara S, Asada S, and Sugimoto Y: Phytoestrogens /flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Research 64, 4346-4352, 2004.
115. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, et al.: Inhibition of Pglycoprotein by natural products in human breast cancer cells. Archives of Pharmacal Research 28, 823-828, 2005.
116. Zhang S, Yang X, and Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Molecular Pharmacology 65, 1208-1216, 2004.
117. Meiyanto E, Hermawan A, and Anindyajati: Natural products for cancer-Targeted therapy: Citrus flavonoids as potent chemoprevent agents. Asian Pacific Journal of Cancer Prevention 13, 427-436, 2012.
118. Hatkevich T, Ramos J, Santos-Sanchez I, and Patel YM: A naringenin-Tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells. Exp Cell Res 2014. http://dx.doi.org/10.1016/j. yexcr.2014.05.017
119. Renugadevi J and Prabu SM: Naringenin protects against cadmiuminduced oxidative renal dysfunction in rats. Toxicology 256, 128-134, 2009.
120. Jain A, Yadav A, Bozhkov AI, Padalko VI, and Flora SJS: Therapeutic efficacy of silymarin and Naringenin in reducing arsenic-induced hepatic damage in young rats. Ecotoxicology and Environmental Safety 74, 607-614, 2011.
121. Hirai S, Kim YI, Goto T, Kang MS, Yoshimura M, et al.: Inhibitory effect of Naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages. Life Science 81, 1272-1279, 2007.
122. Lyu SY and Park WB: Production of cytokine and NO by RAW 264.7 macrophages and PBMC in vitro incubation with flavonoids. Archives of Pharmacal Research 28, 573-581, 2005.
123. Tanakoishikawa Y, Goto M, and Yamaki K: Structure-Activity relations of inhibitory effects of various flavonoids on lipopolysaccharide-induced prostaglandin E2 production in rat peritoneal macrophages: comparison between subclasses of flavonoids. Phytomedicine 13, 310-317, 2006.
124. Fang F, Tang Y, Gao Z, and Xu Q: Novel regulatory mechanism of Naringenin through inhibition of T lymphocyte function in contact hypersensitivity suppression. Biochemical and Biophysical Research Communications 397, 163-169, 2010.
125. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, et al.: Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radical Biology and Medicine 28, 1780-1794, 2000.
126. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 352, 1685-1695, 2005.
127. Chen S, Ding Y, Tao W, Zhang W, Liang T, et al.: Naringenin inhibits TNF-A induced VSMC proliferation and migration via induction of HO-1. Food and Chemical Toxicology 50, 3025-3031, 2012.
128. Lee JJ, Yi H, Kim IS, Kim Y, Nhiem NX, et al.: (2S)Naringenin from Typha angustata inhibits vascular smooth muscle cell proliferation via a G0/G1 Arrest. Journal of Ethnopharmacology 139, 873-878, 2012.
129. Di VC, Bertoni A, Nalin M, Sampietro S, Zanfa M, et al.: The phytoestrogen 8-prenyl Naringenin inhibits agonist-dependent activation of human platelets. Biochimica et Biophysica Acta 1820, 1724-1733, 2012.
130. Amaro MI, Rocha J, Vila-Real H, Eduardo-Figueira M, Mota-Filipe H, et al.: Anti-inflammatory activity of Naringin and the biosynthesised Naringenin by Naringinase immobilized in microstructured materials in a model of DSS-induced colitis in mice. Food Research International 42, 1010-1017, 2009.
131. Collins D, Kopic S, Geibel JP, Hogan AM, Medani M, et al.: The flavonone Naringenin inhibits chloride secretion in isolated colonic epithelia. European Journal of Pharmacology 668(1-2), 271-277, 2011.
132. Kannappan S, Palanisamy N, and Anuradha CV: Suppression of hepatic oxidative events and regulation of iNOS expression in the liver by Naringenin in fructose-Administered rats. European Journal of Pharmacology 645, 177-184, 2010.
133. Yoshida H, Takamura N, Shuto T, Ogata K, Tokunaga J, et al.: The citrus flavonoids hesperetin and Naringenin block the lipolytic actions of TNF-A in mouse adipocytes. Biochemical and Biophysical Research Communications 394, 728-732, 2010.
134. Orsolic N, Gajski G, Garaj-Vrhovac V, Dikic D, Prskalo ZS, et al.: DNA-protective effects of quercetin or Naringenin in alloxaninduced diabetic mice. European Journal of Pharmacology 656, 110-118, 2011.
135. Khan BM, Khan MM, Khan A, Md. Ahmed E, Ishrat T, et al.: Naringenin ameliorates Alzheimer's disease (AD)-Type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochemistry International 61, 1081-1093, 2012.
136. Heo HJ, Kim DO, Shin SC, Kim MJ, Kim BG, et al.: Effect of antioxidant flavanone, Naringenin, from citrus junos on neuroprotection. Journal of Agriculture and Food Chemistry 52, 1520-1525, 2004.
137. Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, et al.: Neuroprotective properties of the natural phenolic antioxidants curcumin and Naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radical Research 39, 1119-1125, 2005.
138. Fu H, Lin M, Katsumura Y, Yokoya A, Hata K, et al.: Protective effects of silybin and analogues against X-ray radiation-induced damage. Acta Biochim Biophys Sin 42, 489-495, 2010.
139. Jagetia GC and Reddy TK: Modulation of radiation-induced alteration in the antioxidant status of mice by NG. Life Sciences 77, 780-794, 2005.
140. Jagetia GC, Venkatesha VA, and Reddy TK: Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. Mutagenesis 18, 337-343, 2003.
141. Maximov PY, Lee TM, and Jordan VC: The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Current Clinical Pharmacology 8, 135-155, 2013.
142. Ruh MF, Zacharewski T, Connor K, Howell J, Chen I, et al.: Naringenin: A weakly estrogenic bioflavonoid that exhibits antiestrogenic activity. Biochemical Pharmacology 5, 1485-1493, 1995.
143. Keiler AM, Zierau O, and Kretzschmar G: Hop extracts and hop substances in treatment of menopausal complaints. Planta Medica 79, 576-579, 2013
144. Zieraua O, Hamanna J, Tischerb S, Schwabb P, Metzb P, Vollmera G, et al.: Naringenin-Type flavonoids show different estrogenic effects in mammalian and teleost test systems. Biochemical and Biophysical Research Communications 326, 909-916, 2005.
145. Breinholt V and Larsen JC: Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay. Chemical in Research in Toxicology, 11, 622-629, 1998.
146. Zand RS, Jenkins DJ, and Diamandis EP: Steroid hormone activity of flavonoids and related compounds. Breast Cancer Research and Treatment 62, 35-49, 2000.
147. Guo D, Wang J, Wang X, Luo H, Zhang H et al.: Double directional ad-justing estrogenic effect of naringin from Rhi-zoma drynariae (Gusuibu). Journal of Ethnopharmacology 138, 451-457, 2011.
148. Kim S and Park TI: Naringenin: a partial agonist on estrogen receptor in T47D-KBluc breast cancer cells. International Journal of Clinical and Experimental Medicine 6, 890-899, 2013.